JESSICA RAVARE: Open Payments
NPI 1194340695 · MARKSVILLE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$747 in 26 payments from 13 companies in 2025. Trend: 2023 $622 · 2024 $544 · 2025 $747
Food & beverage: $747
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 6 | $161 |
| Axsome Therapeutics, Inc. | 1 | $123 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $116 |
| Merck Sharp & Dohme LLC | 2 | $51 |
| GlaxoSmithKline, LLC. | 3 | $51 |
| ABBVIE INC. | 2 | $43 |
| EMD Serono, Inc. | 1 | $40 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| Gilead Sciences, Inc. | 2 | $39 |
| Novo Nordisk Inc | 2 | $29 |
Products named: Auvelity, XIFAXAN, CABENUVA, DOVATO, PIFELTRO, TRELEGY ELLIPTA, QULIPTA, BREZTRI.
Industry payments across LA — which companies pay providers there.
